Antidepressant Treatment of AIDS Related Depression.

Sponsor

GEIGY Pharmaceuticals (Industry)

Overall Status

Completed

CT.gov ID

NCT00000390

Collaborator

(none)

Location

Study Details

Study Description

Brief Summary

To test the effectiveness treating AIDS related depression with imipramine hydrochloride.

Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.

This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.

Condition or Disease	Intervention/Treatment	Phase
Depression	Drug: Imipramine hydrochloride	Phase 2

Detailed Description

To test the effectiveness treating AIDS related depression with imipramine hydrochloride.

Study Design

Study Type:

Interventional

Primary Purpose:

Treatment

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

Patient must be ambulatory and relatively good health. Even if unable to work at least able to partially care care for self and not demented.
May have been alcoholic or drug abuser 6 months previous.
Unspecified
CD4 Unspecified.

Exclusion Criteria:

Non ambulatory patients or those requiring extensive help in self care are excluded.
Non ambulatory patients or those requiring extensive help in self care are excluded.
Current alcohol or drug abuse.
Unspecified